Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Elite Research Center LLC

Neither a doctor nor a teaching hospital

Research payments

$1,108,536

661 payments

Through program year 2025, Elite Research Center LLC is reported as receiving $1,108,536 in research payments, across 661 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $168,650 17
2024 Research $62,808 8
2021 Research $133,870 169
2020 Research $393,297 343
2019 Research $349,911 124

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $501,025 70 payments
  2. AbbVie, Inc. $231,458 25 payments
  3. Novo Nordisk AS $176,665 491 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $104,747 46 payments
  5. Lexicon Pharmaceuticals, Inc. $49,637 2 payments
  6. Gilead Sciences, Inc. $45,004 27 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants $181,446 19 payments
  2. Nn9535-4321 $166,509 489 payments
  3. BAY94-8862 ph 3 conventional in diabetic nephropathy $97,992 40 payments
  4. Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog Versus Continuous Use of NovoLog in Participants With Type 1 Diabetes Mellitus Also Using Insulin Glargine $96,830 10 payments
  5. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk $94,195 19 payments
  6. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function $52,268 8 payments
  7. Efc-14875 $48,510 1 payment
  8. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function $47,649 3 payments
  9. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi $30,350 3 payments
  10. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi $29,183 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record